Selecta Biosciences (SELB) Tops Q2 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. TENB
6. EBAY
7. CMG
8. KLAC
9. GOOG
10. BIIB

Go back to Selecta Biosciences (SELB) Tops Q2 EPS by 14c

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 4, 2022 7:30 AM EDT

Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023

Sarepta extends Option and License agreement in exchange for a $2 million payment and notified Selecta of the achievement of certain pre-clinical milestones triggering a $4 million milestone payment obligation

SEL-302, Selectas wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA) remains on track to initiate a Phase 1 trial in Q4 2022

... More